IN2014MN01467A - - Google Patents

Info

Publication number
IN2014MN01467A
IN2014MN01467A IN1467MUN2014A IN2014MN01467A IN 2014MN01467 A IN2014MN01467 A IN 2014MN01467A IN 1467MUN2014 A IN1467MUN2014 A IN 1467MUN2014A IN 2014MN01467 A IN2014MN01467 A IN 2014MN01467A
Authority
IN
India
Prior art keywords
subject
cells
immature hematopoietic
hematopoietic cells
body weight
Prior art date
Application number
Inventor
Yair Reisner
Lustig Esther Bachar
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IN2014MN01467A publication Critical patent/IN2014MN01467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)

Abstract

A method of treating a subject in need of a non syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells wherein the T cell depleted immature hematopoietic cells comprise less than 5 x 105 CD3+ T cells per kilogram body weight of the subject and wherein the dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject and wherein the T cell depleted immature hematopoietic cells are obtained by separating the T cells from the immature hematopoietic cells by magnetic cell sorting and (b) administering to the subject a therapeutically effective amount of cyclophosphamide wherein the therapeutically effective amount comprises 25 200 mg per kilogram body weight thereby treating the subject.
IN1467MUN2014 2011-12-22 2012-12-20 IN2014MN01467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578917P 2011-12-22 2011-12-22
PCT/IL2012/050541 WO2013093919A2 (en) 2011-12-22 2012-12-20 A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion

Publications (1)

Publication Number Publication Date
IN2014MN01467A true IN2014MN01467A (en) 2015-05-01

Family

ID=48669650

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1468MUN2014 IN2014MN01468A (en) 2011-12-22 2012-12-20
IN1467MUN2014 IN2014MN01467A (en) 2011-12-22 2012-12-20

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN1468MUN2014 IN2014MN01468A (en) 2011-12-22 2012-12-20

Country Status (16)

Country Link
US (5) US10434121B2 (en)
EP (2) EP2793914B1 (en)
JP (3) JP2015504047A (en)
KR (2) KR20140105848A (en)
CN (2) CN104093314A (en)
AU (3) AU2012355989B2 (en)
BR (2) BR112014015960A8 (en)
CA (2) CA2859953A1 (en)
DK (2) DK2793914T3 (en)
ES (2) ES2864323T3 (en)
IN (2) IN2014MN01468A (en)
MX (2) MX370404B (en)
RU (2) RU2657758C2 (en)
SG (3) SG11201403456UA (en)
WO (2) WO2013093919A2 (en)
ZA (2) ZA201405071B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073901B1 (en) 2011-09-08 2020-02-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
AU2012348574A1 (en) 2011-12-08 2014-07-24 Yeda Research And Development Co. Ltd. Mammalian fetal pulmonary cells and therapeutic use of same
BR112014015960A8 (en) * 2011-12-22 2017-07-04 Yeda Res & Dev method for treating an individual in need of a non-syngeneic cell or tissue graft, method for treating an individual in need of a hematopoietic transplant, method for treating an individual in need of a non-syngeneic cell or tissue graft, method for treating an individual in need of an immature hematopoietic cell transplantation, and method for inducing specific donor tolerance in an individual in need of a non-congenital cell or tissue graft
ES2959218T3 (en) 2013-05-09 2024-02-21 Advanced Neuroregenerative Therapies Llc Composition to improve the levels of anti-aging biomarkers in a recipient
US10668109B2 (en) 2015-06-18 2020-06-02 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
PL3322425T3 (en) 2015-07-16 2023-10-09 Yeda Research And Development Co., Ltd. Genetically modified anti-third party central memory T cells and their use in immunotherapy
US20190183930A1 (en) * 2015-08-25 2019-06-20 The Uab Research Foundation Methods for stem cell transplantation
CA3005767A1 (en) * 2015-12-04 2017-06-08 Fred Hutchinson Cancer Research Center Uses of expanded populations of hematopoietic stem/progenitor cells
EP3463402B1 (en) * 2016-05-22 2021-06-23 Yeda Research and Development Co. Ltd. Methods of using pulmonary cells for transplantation and induction of tolerance
CA3026453A1 (en) * 2016-06-03 2017-12-07 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
WO2018134824A1 (en) 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
KR102725761B1 (en) 2017-01-20 2024-11-04 하이델베르크 파마 리서치 게엠베하 Compositions and methods for depletion of CD137+ cells
CN118662615A (en) 2017-03-15 2024-09-20 浩康生物系统公司 Compositions and methods for hematopoietic stem cell transplantation
KR20200089289A (en) * 2017-11-15 2020-07-24 위어드 사이언스 엘엘씨 Method and composition for non-myeloablative bone marrow reconstruction
CN111670052A (en) 2017-11-29 2020-09-15 美真达治疗公司 Compositions and methods for depleting CD5+ cells
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
DK3749334T3 (en) 2018-02-08 2025-02-17 Univ Leland Stanford Junior ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
US11273179B2 (en) * 2018-03-12 2022-03-15 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10881692B2 (en) * 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
AU2019344937A1 (en) * 2018-09-18 2021-04-08 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
EP3856206A1 (en) * 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
US20210380946A1 (en) * 2018-11-01 2021-12-09 Children's Hospital Medical Center Reduced intensity conditioning with melphalan
CN109781987B (en) * 2019-01-09 2022-04-26 暨南大学 Application of terminal effector T cell subset in preparation of kit for auxiliary evaluation of aplastic anemia disease degree
EP3953383A4 (en) * 2019-04-08 2023-01-18 Russell Biotech, Inc. IMPROVED MANUFACTURING PROCESSES FOR CELL-BASED THERAPY
CA3137373A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
RU2723164C1 (en) * 2019-10-07 2020-06-09 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Method for calculating the dose of haematopoiesis precursor cells in a leukocytapheresis product by taking into account the change in the integrity of cell membranes during storage
BR112022008638A2 (en) * 2019-11-05 2022-07-19 Yeda Res & Dev METHOD TO TREAT OR PREVENT AN AUTOIMMUNE DISEASE, AND, IMMATURE HEMATOPOIETIC CELL TRANSPLANTATION AND A THERAPEUTIC EFFECTIVE AMOUNT OF AN ISOLATED POPULATION OF CELLS
CN116194221A (en) * 2020-05-28 2023-05-30 生物磁学解决方案有限责任公司 Compositions and methods for negative selection of naive T cells and B cells using a single antibody
CN117279650A (en) * 2020-12-18 2023-12-22 奥瑟姆健康公司 Cell therapy method
CN112669992B (en) * 2020-12-30 2024-06-11 中国人民解放军总医院 Calculation method of individualized dosage of ATG in haploid hematopoietic stem cell transplantation
RU2764742C1 (en) * 2021-04-09 2022-01-20 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТИО им. академика В.И. Шумакова" Минздрава России) Method for selecting an immunosuppression regimen for young children in the long-term period after liver transplantation
US20250114360A1 (en) * 2022-02-03 2025-04-10 The Regents Of The University Of California Novel regimen for augmenting and extending transplant tolerance
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20010009663A1 (en) * 1993-09-13 2001-07-26 Suzanne T. Ildstad Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6217867B1 (en) 1993-09-13 2001-04-17 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5514364A (en) 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1998020932A2 (en) 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
US6039684A (en) 1997-12-11 2000-03-21 Allegheny University Of The Health Sciences Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
AU2003204277B2 (en) 1997-11-14 2006-03-16 The General Hospital Corporation Treatment of hematologic disorders
JP2001523645A (en) 1997-11-14 2001-11-27 ザ・ゼネラル・ホスピタル・コーポレイション Treatment of hematological disorders
WO1999058977A1 (en) 1998-05-11 1999-11-18 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
US6491917B1 (en) 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients
WO2002040050A1 (en) 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
WO2002040640A2 (en) 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
AU2002239424A1 (en) 2000-11-14 2002-05-27 The University Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients
WO2002089746A2 (en) * 2001-05-09 2002-11-14 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
EP1423503A4 (en) 2001-08-01 2005-08-10 Jewish Hospital Healthcare Ser Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2005023982A2 (en) 2003-05-28 2005-03-17 Univ. Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
US20070141027A1 (en) 2003-05-28 2007-06-21 University Of Louisville Research Foundation Inc. Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
DE102009040716B4 (en) * 2009-09-10 2011-07-14 Miltenyi Biotec GmbH, 51429 Use of CD154 for the identification and separation of non-regulatory T cells from a mixture with regulatory T cells
BR112014015960A8 (en) 2011-12-22 2017-07-04 Yeda Res & Dev method for treating an individual in need of a non-syngeneic cell or tissue graft, method for treating an individual in need of a hematopoietic transplant, method for treating an individual in need of a non-syngeneic cell or tissue graft, method for treating an individual in need of an immature hematopoietic cell transplantation, and method for inducing specific donor tolerance in an individual in need of a non-congenital cell or tissue graft
US20210045900A1 (en) 2019-08-13 2021-02-18 Stryker Corporation Stent braid pattern with enhanced radiopacity

Also Published As

Publication number Publication date
JP6313219B2 (en) 2018-04-18
ZA201405071B (en) 2015-11-25
MX2014007647A (en) 2015-04-13
BR112014015959A8 (en) 2017-07-04
US10434121B2 (en) 2019-10-08
RU2648354C2 (en) 2018-03-23
ES2864323T3 (en) 2021-10-13
US20190358269A1 (en) 2019-11-28
AU2012355990B2 (en) 2017-10-12
WO2013093920A2 (en) 2013-06-27
SG11201403459XA (en) 2014-07-30
WO2013093920A8 (en) 2013-09-12
EP2797421A4 (en) 2015-08-26
WO2013093919A3 (en) 2013-10-10
US20140363437A1 (en) 2014-12-11
AU2016259415A1 (en) 2016-12-08
ZA201405298B (en) 2015-11-25
KR20140105848A (en) 2014-09-02
EP2793914B1 (en) 2021-02-03
WO2013093920A3 (en) 2014-11-27
RU2657758C2 (en) 2018-06-15
HK1202775A1 (en) 2015-10-09
AU2012355989A1 (en) 2014-08-07
CN104093314A (en) 2014-10-08
WO2013093919A2 (en) 2013-06-27
CA2859953A1 (en) 2013-06-27
DK2797421T3 (en) 2020-08-24
ES2811529T3 (en) 2021-03-12
MX370404B (en) 2019-12-11
US20190328793A1 (en) 2019-10-31
BR112014015960A2 (en) 2017-06-13
AU2012355990A1 (en) 2014-07-31
US20140369974A1 (en) 2014-12-18
EP2793914A4 (en) 2016-02-10
US20230039904A1 (en) 2023-02-09
US10369172B2 (en) 2019-08-06
CN104470542A (en) 2015-03-25
JP2015502401A (en) 2015-01-22
BR112014015960A8 (en) 2017-07-04
WO2013093919A8 (en) 2013-08-22
CA2859952C (en) 2023-04-04
CA2859952A1 (en) 2013-06-27
JP2015504047A (en) 2015-02-05
DK2793914T3 (en) 2021-04-26
AU2012355989B2 (en) 2016-12-15
SG10201801905WA (en) 2018-04-27
EP2797421A2 (en) 2014-11-05
MX2014007648A (en) 2015-03-19
BR112014015959A2 (en) 2017-06-13
KR102109643B1 (en) 2020-05-29
US11504399B2 (en) 2022-11-22
EP2797421B1 (en) 2020-05-20
SG11201403456UA (en) 2014-07-30
IN2014MN01468A (en) 2015-05-01
KR20140107564A (en) 2014-09-04
US11497776B2 (en) 2022-11-15
EP2793914A2 (en) 2014-10-29
RU2014129632A (en) 2016-02-10
JP2018080201A (en) 2018-05-24
AU2016259415B2 (en) 2018-04-26
HK1202810A1 (en) 2015-10-09
RU2014128479A (en) 2016-02-10

Similar Documents

Publication Publication Date Title
IN2014MN01467A (en)
Poggi et al. How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive
WO2011002721A8 (en) Non-human mammal model of human hematopoietic cancer
WO2011139628A8 (en) Generation of anterior foregut endoderm from pluripotent cells
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
RU2010153362A (en) METHODS FOR TREATING INFLAMMATORY DISEASES OF THE COLUM
US20120201791A1 (en) Methods of treating diseases or conditions using mesenchymal stem cells
NZ591293A (en) Methods and compositions for treatment of bone defects with osteogenic placental adherent cells (OPACs)
GB2434157A (en) Platelets from stem cells
EP2603227A4 (en) Improved hematopoietic stem and progenitor cell therapy
RU2013151632A (en) METHOD OF JOINT CONDITIONING AND CHEMOSELECTION IN ONE CYCLE
NZ609731A (en) Compositions of adult organ stem cells and uses thereof
RU2014146170A (en) METHODS FOR TREATING DIABETES AND / OR IMPROVING SURVIVAL OF PANCREATIC ISLANDS AFTER TRANSPLANTATION
EP2593115A4 (en) TREATMENT OF IMMUNE DISORDERS WITH MEDIATION BY LYMPHOCYTES T
GB2500161A (en) Enhancement of allogeneic hematopoietic stem cell transplantation
IL316897A (en) Compositions and methods for preparing engineered lymphocytes for cell therapy
CA2837895C (en) Methods of treating or preventing neurological diseases
PH12012502233A1 (en) Methods and compositions for inhibition of treg cells
RU2012148391A (en) METHODS FOR IDENTIFICATION, ISOLATION, EMISSION AND ENRICHMENT OF TR1 CELL POPULATIONS, Tr1 CELL POPULATIONS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR MONITORING THE EFFECT OF THERAPY
WO2021015615A8 (en) Low density cell culture
MX339746B (en) Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy.
RU2012104553A (en) CELLS PRODUCED FROM CARDIAL FABRIC
MY199770A (en) Method for culturing cord blood-derived natural killer cells using transformed t cells
CA2836488C (en) Methods for treating obesity and/or metabolic syndrome
WO2020227492A3 (en) Targeting otub1 in immunotherapy